Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products that meet patients' unmet needs and solve therapeutic problems, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported total revenues of USD12.6m in the first quarter 2019 compared to USD23.4m in the first quarter of 2018.
The firm's net loss for the first quarter 2019 was USD14.7m or USD0.59 loss per share.
Keith J Kendall, Aquestive chief executive officer, said, 'We started the year focused on the commercial, regulatory and development milestones that we believe will catalyse our growth and bring value to shareholders. We are progressing as planned across our key initiatives, including the launch of Sympazan, the initiation and execution of a crossover study for Libervant, agreeing with the FDA to move forward with the NDA filing process for that asset, as well as the initiation of the Phase 1 Proof of Concept study for AQST-108.'
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development